Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol.
Ninomiya K, Ichihara E, Hotta K, Sone N, Murakami T, Harada D, Oze I, Kubo T, Tanaka H, Kuyama S, Kishino D, Bessho A, Harita S, Katsui K, Tanimoto M, Kiura K. Ninomiya K, et al. Among authors: oze i. Clin Lung Cancer. 2017 Mar;18(2):245-249. doi: 10.1016/j.cllc.2016.08.001. Epub 2016 Oct 19. Clin Lung Cancer. 2017. PMID: 27847247 Clinical Trial.
Impact of multiple alcohol dehydrogenase gene polymorphisms on risk of upper aerodigestive tract cancers in a Japanese population.
Oze I, Matsuo K, Suzuki T, Kawase T, Watanabe M, Hiraki A, Ito H, Hosono S, Ozawa T, Hatooka S, Yatabe Y, Hasegawa Y, Shinoda M, Kiura K, Tajima K, Tanimoto M, Tanaka H. Oze I, et al. Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3097-102. doi: 10.1158/1055-9965.EPI-09-0499. Epub 2009 Oct 27. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19861527
Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
Nogami N, Hotta K, Segawa Y, Takigawa N, Hosokawa S, Oze I, Fujii M, Ichihara E, Shibayama T, Tada A, Hamada N, Uno M, Tamaoki A, Kuyama S, Ikeda G, Osawa M, Takata S, Tabata M, Tanimoto M, Kiura K. Nogami N, et al. Among authors: oze i. Acta Oncol. 2012 Jul;51(6):768-73. doi: 10.3109/0284186X.2011.648342. Epub 2012 Jan 27. Acta Oncol. 2012. PMID: 22283472 Clinical Trial.
Time to first cigarette and lung cancer risk in Japan.
Ito H, Gallus S, Hosono S, Oze I, Fukumoto K, Yatabe Y, Hida T, Mitsudomi T, Negri E, Yokoi K, Tajima K, La Vecchia C, Tanaka H, Matsuo K. Ito H, et al. Among authors: oze i. Ann Oncol. 2013 Nov;24(11):2870-5. doi: 10.1093/annonc/mdt362. Epub 2013 Sep 6. Ann Oncol. 2013. PMID: 24013511 Free article.
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience.
Kato Y, Hotta K, Takigawa N, Nogami N, Kozuki T, Sato A, Ichihara E, Kudo K, Oze I, Tabata M, Shinkai T, Tanimoto M, Kiura K. Kato Y, et al. Among authors: oze i. Cancer Chemother Pharmacol. 2014 May;73(5):943-50. doi: 10.1007/s00280-014-2425-9. Epub 2014 Mar 16. Cancer Chemother Pharmacol. 2014. PMID: 24633759
216 results